Alio

by Alio Inc.  · Based in United States → — AI-Driven Remote Patient Monitoring for Chronic Conditions
Cardiology Endocrinology Nephrology
Website
Claim this tool
Is this the maker? Claim the company →

Contact vendor for pricing details.
Regulatory Status Disclosed

Overview

Alio Inc. is a medical technology company specializing in an AI-driven remote patient monitoring (RPM) platform. The Alio System consists of a wearable SmartPatch, a bedside Hub, and a clinician-facing Portal. The SmartPatch non-invasively collects physiological data, which is then transmitted via the Hub to the Alio Cloud. Alio’s cloud-based algorithms, powered by artificial intelligence, analyze this data to provide actionable insights, predictive analytics, and notifications to clinical care teams. This platform is designed to enable proactive, continuous monitoring of patients with chronic conditions, particularly those with end-stage kidney disease (ESKD) undergoing hemodialysis, and is also being adapted for conditions like heart failure and acute monitoring. The system aims to improve patient outcomes, reduce hospitalizations, and enhance visibility for physicians in both in-center and home care settings. Note: This tool is a remote patient monitoring system and not a physician directory.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Wearable SmartPatch for non-invasive physiological data collection
  • Alio Hub for secure data transmission to the cloud
  • Clinician-facing Alio Portal for data visualization and interaction
  • AI-powered algorithms for data analysis and actionable insights
  • Continuous 24/7 remote patient monitoring
  • Measures heart rate, skin temperature, hemoglobin, hematocrit, potassium, and auscultation sound data
  • Provides notifications and predictive analytics for timely interventions
  • Encrypted and HIPAA compliant data handling
  • Designed for integration into existing clinician workflows

Use Cases

  • Remote monitoring of end-stage kidney disease (ESKD) patients undergoing hemodialysis
  • Monitoring of other chronic conditions such as heart failure
  • Acute monitoring applications
  • COVID-19 monitoring
  • Enhancing safety and visibility for home hemodialysis
  • Reducing hospitalizations and improving patient outcomes

What Physicians Need to Know

Key Capabilities
Alio's platform provides non-invasive, wireless remote patient monitoring via a SmartPatch, hub, and clinician-facing portal. It monitors critical metrics including hematocrit, hemoglobin, potassium, auscultation sound data, heart rate, and skin temperature. The system utilizes AI to analyze data, generate actionable insights, predictive analytics, and timely notifications for clinical care teams, particularly for patients with chronic conditions like end-stage kidney disease (ESKD) and expanding to heart failure.
Clinical Utility
The Alio platform enables proactive, continuous monitoring of patients, potentially reducing the need for frequent invasive tests and in-person visits. It supports earlier clinical interventions, aiming to decrease complications and hospitalizations for individuals with chronic conditions. By providing clinical-grade data and AI-driven insights, it enhances chronic disease management and offers peace of mind to patients.
Integration Options
The Alio system comprises a SmartPatch, a hub for data transmission (via Bluetooth to the hub, then cellular to the cloud), and a web-based clinician portal. The portal is designed to integrate into existing clinician workflows. Alio has partnered with Carium, a Care Experience Platform, to seamlessly fit its solutions into clinician workflows and broaden access. Alio IT Solutions also offers services for ETL/ELT pipelines for EHR, claims, labs, and devices, indicating potential for deeper data integration with healthcare systems.
Compliance Status
Alio's platform is FDA-cleared, having received two clearances: one in 2022 for skin temperature, auscultation sound data, and heart rate, and another in 2023 for hematocrit, hemoglobin, and potassium (the world's first non-invasive potassium monitor). The Alio Cloud database is encrypted and HIPAA compliant. It is intended as a secondary, adjunct patient monitor for healthcare providers in clinical and non-clinical settings, not as a replacement for standard-of-care practices or a stand-alone diagnostic tool.
Pricing Model
Specific pricing models for Alio's healthcare platform are not publicly disclosed in the available information.
User Experience
The SmartPatch is designed to be non-invasive, patient-friendly, and 'forgettable,' aiming to increase user compliance by eliminating the need for blood draws, finger pricks, or patient interaction with the data transmission process. The system is described as 'plug and play' for patients, with a bedside hub automatically relaying data.
Support Quality
Information regarding specific support quality details for Alio is not publicly available in the provided search results.
Implementation Complexity
The patient-facing components (SmartPatch and Hub) are designed for ease of use, described as 'plug and play' with no patient setup required. The clinician portal integrates into existing workflows. Alio IT Solutions offers services to assist with evaluation, deployment, and management of AI, suggesting support for implementation.
Evidence Base
Alio's technology has received two FDA clearances based on clinical research demonstrating accuracy and reliability. Clinical studies have validated its ability to accurately assess abnormal potassium levels and measure hemoglobin and hematocrit, showing close alignment with standard blood-based laboratory methods. The ongoing CAVA study is further evaluating the SmartPatch for non-invasive monitoring from the calf, with preliminary data indicating high correlation to previous FDA validation studies and gold standards.
Physician Tip

Leverage Alio for continuous, non-invasive monitoring of key physiological metrics in chronic disease management, especially for ESKD patients. Utilize the AI-driven insights and notifications for early intervention and to prioritize patient follow-up, potentially reducing complications and hospitalizations. Remember that Alio is an adjunct monitor and should complement, not replace, comprehensive patient assessment and standard-of-care practices. Consider its utility for enhancing home hemodialysis safety and visibility.

Alio's platform is designed with a hub-and-portal architecture for data flow to clinicians. Its partnership with Carium aims for seamless integration into existing clinician workflows. For deeper integration with Electronic Health Records (EHRs), Alio IT Solutions offers services for data pipelines and AI integration, suggesting capabilities to connect with various healthcare data systems. This allows for the potential to incorporate Alio's real-time patient-generated data into a broader clinical context.

Details

Category Endocrinology & Metabolic AI, Patient Engagement & Education, Wearables & Remote Monitoring (RPM)
Pricing Contact vendor for pricing details.
  • Not publicly available; contact Alio Inc
  • directly for commercial agreements and pricing information
DeploymentCloud-based (Alio Cloud, Alio Portal) with a physical wearable device (SmartPatch) and a bedside Hub for data transmission.
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

Alio Inc. has received multiple FDA 510(k) clearances. K223073, cleared on March 17, 2023, is for a wireless remote monitoring system intended for use by healthcare providers to collect physiological data in clinical and non-clinical settings. This includes measurements of heart rate, skin temperature, hemoglobin (Hgb), hematocrit (Hct), auscultation sound data, and a qualitative risk assessment of abnormal potassium levels, for general care patients and patients with end-stage kidney disease (ESKD) who are 18 years of age or older.
Integrations
EHR Not specified
Specialties Cardiology, Endocrinology, Nephrology

What the Web Says

Alio (alio.ai) is a platform designed to streamline healthcare operations, particularly focusing on administrative tasks and patient engagement. Reviews suggest it aims to improve efficiency for healthcare providers and enhance the patient experience through automation and integrated tools.

Overall: Mixed

Strengths

  • Improved administrative efficiency for healthcare providers
  • Enhanced patient engagement features
  • Streamlined scheduling and communication
  • Potential for reduced operational costs
  • User-friendly interface reported by some users
  • Integration capabilities with existing systems

Limitations

  • Limited detailed reviews from physicians specifically
  • Potential learning curve for new users
  • Cost of implementation and subscription not widely discussed in public reviews
  • Scalability for very large healthcare systems unclear from available data
  • Specific impact on patient outcomes not frequently highlighted in reviews
  • Reliance on internet connectivity for cloud-based features

Based on reviews from: Alio.ai website, Healthcare IT news articles, Tech review sites (general), Reddit (limited mentions), G2 (limited reviews), Capterra (limited reviews)

Last updated: 2026-07-18

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Alio

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Clinical Trials Arena
Alio starts trial to expand label for remote monitoring device
Alio has initiated the CAVA study to expand the use case of its SmartPatch technology for non-invasive remote monitoring of health metrics from the calf in dialysis patients without vascular access sites. The SmartPatch was previously cleared by the US FDA for monitoring various health metrics from arm-based vascular access sites.
2024-09
Business Wire
Alio Launches Calibration and Validation (CAVA) Study to Expand Alio Platform's FDA Clearance Beyond the Vascular Access for Use in a Broader Range of Patients
Alio, Inc. announced the launch of its multi-center and international CAVA study to expand its FDA-cleared SmartPatch technology beyond dialysis patients with vascular access sites. The study aims to validate non-invasive monitoring of critical health metrics from the calf for a wider range of chronic conditions.
2024-09
Hospital Management
Alio Advances FDA Clearance with New CAVA Study to Broaden Platform's Patient Use
Alio, Inc. is conducting an international study, the CAVA protocol, to extend its AI-powered SmartPatch technology beyond dialysis to broader chronic condition management. This study will assess the SmartPatch's ability to non-invasively monitor key health metrics from the calf.
2024-09
Medical Product Outsourcing
Alio's SmartPatch Technology Under Review in New Study
Alio Inc. has launched a multi-center and international investigational study, the CAVA study, to expand its FDA-cleared SmartPatch technology beyond dialysis patients. The study will assess non-invasive monitoring of critical health metrics from the calf, including hemoglobin, hematocrit, potassium, SpO2, blood volume, and heart rate.
2024-10
PR Newswire
Alio Becomes World's First Non-invasive Potassium Monitor
Alio, Inc. announced its latest FDA clearance, making its SmartPatch technology the world's first non-invasive potassium monitor. This clearance expanded its remote patient monitoring platform to include hematocrit, hemoglobin, and potassium, in addition to previously cleared metrics.
2023-03
AALL IR Room (via PR Newswire)
Alio Secures Commercial Customer, Premier Dialysis, Further Extending its Reach Within the Kidney Disease Landscape
Alio, Inc. announced its official launch with commercial customer Premier Dialysis, aiming to improve the quality of life for dialysis patients through better management of their condition. This partnership follows Alio's second FDA clearance.
2023-09
PR Newswire
Alio and Carium Announce Partnership to Increase Access to Healthcare Through Remote Patient Monitoring
Alio, Inc. and Carium partnered to improve health outcomes for patients with chronic conditions and increase healthcare accessibility through Alio's remote patient monitoring platform. The collaboration aims to leverage innovative technology for better chronic care management.
2023-03
Renal Interventions
Alio remote monitoring technology receives first FDA 510(k) clearance
Alio announced it received its first US Food and Drug Administration (FDA) 510(k) clearance for its remote monitoring system. This system is intended for healthcare professionals to intermittently collect physiological data, including skin temperature, auscultation sound data, and heart rate, in home-use settings.
2022-04

Videos

Product demos, reviews, and walkthroughs for Alio.

View all on YouTube

Frequently Asked Questions

Alio integrates into a physician's workflow through its platform, which consists of a wearable SmartPatch, a bedside hub, and a clinician-facing web portal. The SmartPatch wirelessly transmits clinical-grade data to the Alio cloud, where AI algorithms analyze it and provide actionable insights, predictive analytics, and notifications directly to clinical care teams. This system is designed to be 'plug and play,' requiring no setup from the patient and easily integrating into existing infrastructure and workflows for dialysis staff.
Alio is primarily designed for non-invasive, wireless remote patient monitoring of individuals with chronic conditions, specifically those with end-stage kidney disease (ESKD) undergoing dialysis. The SmartPatch monitors metrics like hematocrit, hemoglobin, potassium, auscultation, heart rate, and skin temperature. The company is also conducting studies to expand its use case to other chronic conditions like heart failure.
Alio's SmartPatch technology is cleared by the U.S. FDA for measuring multiple health metrics in patients undergoing dialysis. While the search results confirm FDA clearance, they do not explicitly detail specific HIPAA certifications for Alio itself. However, AI systems processing Protected Health Information (PHI) in digital health platforms must comply with HIPAA Privacy and Security Rules, requiring appropriate technical, administrative, and contractual safeguards, including Business Associate Agreements (BAAs) with vendors.
Alio differentiates itself through its non-invasive, multi-metric SmartPatch technology that continuously captures clinical-grade data, including the world's first non-invasive potassium monitor. Unlike traditional methods or some other RPM devices, it aims to provide actionable, predictive insights without the need for blood draws or finger pricks, improving patient experience and potentially reducing hospitalizations.
The search results indicate that Alio is a privately held company and does not publicly disclose its pricing model. Information regarding its valuation and funding rounds is available, but specific pricing for its platform and SmartPatch technology for healthcare providers is not provided.
Currently, Alio's FDA-cleared technology primarily focuses on monitoring specific metrics (hematocrit, hemoglobin, potassium, auscultation, heart rate, skin temperature) for patients with end-stage kidney disease undergoing dialysis. While the company is actively working to expand its label and monitor additional metrics like blood pressure and SpO2, and extend suitability to other chronic conditions, these expansions are still under investigation or nearing FDA validation.

Related Tools

SureMediks ProView
SureMediks (Rasimo Systems, LLC)
Clinical Decision Support & Reference
SureMediks is an AI-powered clinical decision support and metabolic health platform that automates care workflows for specialists, providing AI-generated patient summaries, automated chart review, and real-time biometric alerts.
SigXA
SigXA
Documentation & Scribing
SigXA is an AI medical scribe and ambient assistant that transforms patient encounters into structured clinical documentation, specifically tuned for endocrinology teams to manage hormonal and metabolic conditions with protocol-driven longitudinal monitoring.
Paid, free trial
Nirmitee.io Diabetes Care Intelligence
Nirmitee.io
Endocrinology & Metabolic AI
Nirmitee.io Diabetes Care Intelligence is an AI-powered platform that integrates CGM data, analyzes 14-day CGM patterns, and correlates them with insulin doses, meal timing, and activity to generate specific dosing recommendations for personalized diabetes management.
Wellma for Practitioners
Wellma
Clinical Decision Support & Reference
Wellma for Practitioners is an AI co-pilot that extends care plans between sessions, providing real-time client insights, structured follow-up, and pre-session briefs for metabolic health conditions.
Virta Health
Virta Health
Endocrinology & Metabolic AI
Virta Health offers a virtual health program focused on reversing Type 2 diabetes, prediabetes, and obesity through a nutrition-first approach, continuous remote care, and personalized coaching.
Hybrid
PNOĒ
PNOĒ
Endocrinology & Metabolic AI
PNOĒ is a science-backed cardiometabolic analyzer that performs comprehensive breath-based assessments to measure 23 biomarkers, including VO₂ max, resting metabolic rate (RMR), fat burn efficiency, and biological age. It delivers a 360° snapshot of an individual's physiology by analyzing how oxygen flows through the lungs, heart, and cells. The insights generated are used to personalize nutrition, exercise, and longevity plans.
Varies

See all Endocrinology & Metabolic AI tools →

Suggest an Edit → | Last Verified: 2026-04-17 | First Added: 2026-04-17
AI Tool Finder
AI-powered search. Results may not be comprehensive.